Endocrinology

The primary endpoint was non-inferiority in HbA1c levels after 26 weeks.

A further understanding of the role SARS-CoV-2 plays in T2D incidence can add an important component to benefit and risk considerations to prevent COVID-19.

Look back at several quick video interviews discussing the expanding role of artificial intelligence, how RSV treatment has evolved, and much more.

This decision marks the second time the FDA has issued a complete response letter (CRL) for dasiglucagon to treat hypoglycemia in patients 7 days and up with congenital hyperinsulinism.

The panel examines potential long-term effects of central precocious puberty treatment on bone density and spermatogenesis in male patients.

Experts address common misconceptions about the timing of central precocious puberty treatment initiation and discontinuation, highlighting research on outcomes for therapy started before age 7 and continued beyond age 12.

Linda DiMeglio, MD, MPH, joined us to discuss the “Consensus Guidance for Monitoring Persons with Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes."

Andrew Dauber, MD, MMSc, of Children's National Hospital joined us to talk PGHD and the role of the pediatrician when it comes to treatment.

Pediatric endocrinologists explore comprehensive, individualized treatment strategies for Central Precocious Puberty that extend beyond considerations of chronological and bone age.

The panel examines the efficacy and safety profiles of gonadotropin-releasing hormone analogue (GnRHa) treatments in managing Central Precocious Puberty.

Key opinion leaders analyze current treatment guidelines for Central Precocious Puberty while offering insights on navigating treatment selection in scenarios lacking established protocols.

The panel explores the impact of early versus delayed diagnosis and treatment initiation on long-term outcomes in Central Precocious Puberty patients.

Key opinion leaders offer insights into the pathogenesis and essential features of CPP, along with additional symptoms that clinicians should monitor.

In the field of pediatric care, the understanding and management of central precocious puberty (CPP) is evolving, thanks to emerging data and individualized treatment approaches.

The USPSTF statement aligns with the 2015 recommendation on insufficient evidence for pregnancy iron deficiency screening or supplementation.

The most common comorbid conditions were endocrinopathies (10%), trisomy 21(5%), and attention-deficit/hyperactivity disorder (4%).

Diamyd to improve glycemic control in recently diagnosed stage 3 Type 1 Diabetes patients with the genotype HLA DR3-DQ2 was granted Fast Track designation by the FDA in February 2024.

"Taken together, our findings suggest the relative protection associated with having a mother versus father with type 1 diabetes is a long-term effect that extends into adult life," stated study investigators.

The decision is based on statistical significance achieved in the T2NOW trial, which demonstrated reduction of A1C.

The primary outcome was an elevated HbA1c level greater than or equal to 5.7% (prediabetes or undiagnosed presumed T2D).

Drugs like semaglutide and liraglutide were dispensed at unprecedented increased rates for adolescents and young adults over a span of just 4 years.

Investigators found that higher baseline HbA1c was associated with greater T2D risk.

The FDA has approved lutetium Lu 177 dotatate for pediatric patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

The single-arm study has an estimated enrollment of 93 participants, made up of females aged 2 to 8 years and males aged 2 to 9 years with CPP.

Lara Smith, DNP, APRN, CPNP-AC/PC, provides case-based examples of endocrine emergencies in the pediatric ICU, based on her session presented at the 45th NAPNAP National Conference.